NewLink Genetics Corp. (NASDAQ:NLNK) shares traded down 2.3% during mid-day trading on Monday . The company traded as low as $10.72 and last traded at $10.75, with a volume of 148,572 shares changing hands. The stock had previously closed at $11.00.

A number of research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of NewLink Genetics Corp. from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research report on Tuesday, July 26th. Cantor Fitzgerald restated a “buy” rating and set a $62.00 target price on shares of NewLink Genetics Corp. in a research report on Friday, April 29th. Stifel Nicolaus decreased their target price on shares of NewLink Genetics Corp. from $63.00 to $23.00 and set a “buy” rating for the company in a research report on Tuesday, May 10th. Robert W. Baird restated a “buy” rating on shares of NewLink Genetics Corp. in a research report on Monday, May 16th. Finally, Jefferies Group restated a “hold” rating and set a $10.00 target price on shares of NewLink Genetics Corp. in a research report on Wednesday, May 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $23.29.

The stock’s market capitalization is $309.31 million. The firm has a 50-day moving average price of $10.98 and a 200 day moving average price of $15.69.

NewLink Genetics Corp. (NASDAQ:NLNK) last posted its earnings results on Friday, July 29th. The company reported ($1.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.77) by $0.35. Analysts expect that NewLink Genetics Corp. will post ($3.06) EPS for the current year.

Several hedge funds and institutional investors recently bought and sold shares of NLNK. California State Teachers Retirement System increased its position in NewLink Genetics Corp. by 1.7% in the fourth quarter. California State Teachers Retirement System now owns 38,523 shares of the company’s stock worth $1,402,000 after buying an additional 636 shares during the period. Dimensional Fund Advisors LP increased its position in NewLink Genetics Corp. by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 48,507 shares of the company’s stock worth $1,765,000 after buying an additional 300 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. increased its position in NewLink Genetics Corp. by 134.1% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 54,775 shares of the company’s stock worth $1,993,000 after buying an additional 31,375 shares during the period.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.